

# Special Issue

## Recent Advances in Glioblastoma

### Message from the Guest Editor

Dear colleagues, The last few years have brought much needed knowledge on the biology, therapeutic resistance, and interaction with the immune system of malignant gliomas. However, progress in their treatment is still stagnant, and these primary brain tumors remain incurable. In addition, tumor cells alter the function of the surrounding brain, which greatly contributes to their morbidity and reduces the chances of patients to access treatment. The complex relationship between tumor cells and their environment is thus also a key to reach a cure. This Special Issue will focus on new advances in the pathophysiology of GBM, its relationship with the normal brain cells and the immune system, and novel approaches to tackle treatment resistance and eradicate this deadly brain cancer. We look forward to your contributions. Prof. Dr. Pierre A. Robe

### Guest Editor

Prof. Dr. Pierre A. Robe

Department of Neurology and Neurosurgery, University Hospital of Utrecht, Heidelberglaan, 100 3584 Cx Utrecht, The Netherlands

### Deadline for manuscript submissions

closed (31 December 2020)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/31786](https://mdpi.com/si/31786)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)